Professor Matthew Kiernan

That's where it's going to be.

And we're going to see what are those levels, but we can't really, at the moment, we haven't done large population studies to know what that range should be.

And also, as you say, we don't want to panic people.

You don't have a range.

That's cutting edge research now.

To see where you fit.

I'd say with absolute guarantee they will be.

And you'll be going to the doctor with a blood result, like you do now with a full blood count hemoglobin, and they'll say, oh, your neurofilament is slightly high.

This is the treatment to bring it down towards roughly normal levels.

Oh, that's really high.

We need to do some more investigations on that one.

We need to do a lumbar puncture and MRI scan.

So I think it's going to start to determine...

the way forward.

But then also linked to that, we're going to start having treatments.

And we have now two treatments for Alzheimer's disease, monoclonal antibodies, and there's a lot more on the horizon coming through.

So it's very much a therapeutic era.

Wow.

Yeah.

You'd be seeing it as a neurologist, but it's a big deal.